Browsing Tag
Novartis AG
9 posts
How pediatric biologic approvals are transforming hidradenitis suppurativa treatment
Novartis AG expands Cosentyx approval to adolescents with hidradenitis suppurativa. Discover what this means for dermatology biologics and investors.
Can RNA medicines really reach the heart? Atrium Therapeutics (Nasdaq: RNA) is putting $270m on the line
Atrium Therapeutics launches with $270 million to advance RNA medicines for rare genetic cardiomyopathies. Find out why investors are watching closely.
Dr. Reddy’s (NSE: DRREDDY) signals dual-track U.S. growth strategy with abatacept biosimilar BLA acceptance and OTC eye-care expansion
Discover how Dr. Reddy’s FDA-accepted abatacept biosimilar and OTC eye-care launch are reshaping its U.S. growth and investor outlook.
Camurus resubmits Oclaiz for FDA review as subcutaneous acromegaly therapy eyes June 2026 decision
Camurus's Oclaiz is back in FDA review for acromegaly. Find out what the June 2026 decision could mean for U.S. access and endocrine market disruption.
Will Novartis’ oral drug iptacopan change the game in myasthenia gravis treatment?
Novartis gains FDA orphan designation for iptacopan in myasthenia gravis. Explore how this oral drug could shift neurology and rare disease strategy.
Novartis makes $12bn bet on RNA medicine with Avidity Biosciences acquisition to expand rare-disease pipeline
Find out why Novartis’s $12 billion Avidity Biosciences deal marks a turning point for big pharma’s RNA-therapy ambitions.
Novartis is buying its way into the next wave of genetic medicine — Avidity could be the entry point
Discover how Novartis’s proposed acquisition of Avidity Biosciences at over $70 a share could reshape its pipeline strategy and disrupt the rare-disease biotech space.
Why is Novartis acquiring Tourmaline Bio—and how does pacibekitug fit into its cardiovascular pipeline?
Novartis is acquiring Tourmaline Bio in a $1.4B deal to advance pacibekitug, a promising anti-IL-6 therapy for atherosclerotic cardiovascular disease.
Novartis to acquire Cadent Therapeutics in $770m deal to bolster neuropsychiatric pipeline
Find out how Novartis plans to transform neuroscience with its $770M acquisition of Cadent Therapeutics and its novel CNS treatment pipeline.